Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acceptance to participate in the study, signing the informed consent document before conducting any study procedures.~2. Patient with HIV infection older than 18 years.~3. Treatment with darunavir/ritonavir once a day and tenofovir/emtricitabine or abacavir/lamivudine during at least 4 weeks at the moment of the screening~4. Plasma HIV RNA levels below 50 copies / ml for at least 6 months (two separate measurements at least 6 months with viremia \<50 copies / ml between both).~5. HbsAg negative~Exclusion Criteria:~1. Pregnant or breastfeeding woman~2. Evidence of Lamivudine resistance (any previous genotype with mutation M184V/I or K65R) and/or to darunavir (population genotype show any of the following mutations: V11I, V32I, L33F, I47V, I50V, I54L/M, G73S, T74P, L76V, I84V, L89V).~3. History of virology failure (two consecutive viral loads above 200 copies/ml) while the patient was receiving a regimen with lamivudine or emtricitabine, with the following exceptions:~   * Do not consider an exclusion criterion if the genotype performed at the time of failure does not demonstrate resistance to lamivudine and darunavir (see criteria 2).~  * Do not consider an exclusion criteria in the absence of genotype if after the episode turns to maintain a viral load \<50 copies / ml with a treatment composed of lamivudine or emtricitabine + a nucleoside + a non-nucleoside.~4. History of abandonment of treatment including lamivudine or emtricitabine, with the following exception:~   - Viral load prior to abandonment was \<50 copies / ml and subsequent reintroduction of the same treatment or another treatment consisting of lamivudine or emtricitabine + a nucleoside + a non-nucleoside returns to maintain viral load below 50 copies / ml .~5. Previous treatment with bitherapy or monotherapy with lamivudine or emtricitabine~6. Previous treatment with bitherapy or monotherapy with a regimen with a protease inhibitor that is terminated by viral rebound, when the absence of a genotypic resistance test available after viral rebound allow discard the resistance mutations either drug used.~7. The use of concomitant medication not permitted~8. Presence of active acute infection, including opportunist infection that a judge of investigator that can difficult the participation in the trial~9. Any laboratory results of the following: hemoglobin\<8,0 g/dl; neutrophils \<750 cells/µl; platelets \<50.000 cell/µl; creatinine ≥ 1,5 ULN (upper limit of normal)~10. Any clinical or analytic event that, in the investigator judgment, condition the patient safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Darunavir/Ritonavir + 2 nucleos(t)idos (Type: ACTIVE_COMPARATOR): Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
- Darunavir/ritonavir + Lamivudine (Type: EXPERIMENTAL): Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete